TY - JOUR
T1 - An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder
AU - Groenman, Annabeth P.
AU - Schweren, Lizanne J. S.
AU - Dietrich, Andrea
AU - Hoekstra, Pieter J.
PY - 2017/4
Y1 - 2017/4
N2 - Introduction: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). Although methylphenidate has a well-established evidence base for treating ADHD, its long-term benefits are unclear.Areas covered: Physical adverse effects, psychiatric adverse events and brain developmentExpert opinion: Some physical adverse events have been described (e.g. sleep disturbances, growth reduction, loss of appetite), although most are of transient nature. Psychiatric adverse events seem more related to the diagnosis ADHD itself, and not stimulant treatment. Concluding, short-to-mid-term use (i.e., up to 2years) stimulants are relatively safe, but much less is known about longer-term efficacy and safety of these drugs.
AB - Introduction: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). Although methylphenidate has a well-established evidence base for treating ADHD, its long-term benefits are unclear.Areas covered: Physical adverse effects, psychiatric adverse events and brain developmentExpert opinion: Some physical adverse events have been described (e.g. sleep disturbances, growth reduction, loss of appetite), although most are of transient nature. Psychiatric adverse events seem more related to the diagnosis ADHD itself, and not stimulant treatment. Concluding, short-to-mid-term use (i.e., up to 2years) stimulants are relatively safe, but much less is known about longer-term efficacy and safety of these drugs.
KW - ADHD
KW - stimulant treatment
KW - methylphenidate
KW - safety
KW - DEFICIT-HYPERACTIVITY DISORDER
KW - FUNCTIONAL MAGNETIC-RESONANCE
KW - OF-THE-LITERATURE
KW - SERIOUS CARDIOVASCULAR EVENTS
KW - COMORBID TIC DISORDER
KW - LA-TOURETTES SYNDROME
KW - STIMULANT TREATMENT
KW - SUBSTANCE USE
KW - METHYLPHENIDATE TREATMENT
KW - MULTIMODAL TREATMENT
U2 - 10.1080/14740338.2017.1301928
DO - 10.1080/14740338.2017.1301928
M3 - Review article
SN - 1474-0338
VL - 16
SP - 455
EP - 464
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
IS - 4
ER -